J9019 Asparaginase (HCPCS) Reimbursement & Policy

HCPCS Level II code J9019 represents the injectable antineoplastic agent asparaginase (erwinaze), billed per 1,000 IU unit. The code is used when this drug is supplied and administered in clinical settings that deliver parenteral oncology therapies. Nationally, biologic and chemotherapy drug billing codes like J9019 are important for tracking utilization, payer coverage, and cost management for high-cost specialty medications.

This analysis covers major national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context and common sites of service, plus guidance on the types of benchmarks and policy metrics typically associated with drug J-codes: utilization units, site-of-service distribution, and payer coverage patterns. Where available, the publication summarizes typical modifiers and billing considerations related to specialty drug administration.

The report is intended to inform billing managers, revenue cycle staff, and policy analysts about the role of J9019 in oncology drug billing, what to expect in payer negotiations, and which operational metrics are relevant for monitoring drug administration and reimbursement. Data not available in the input will be noted as such in relevant sections.

Billing Code Overview

HCPCS Level II code J9019 describes an injection of asparaginase (erwinaze) supplied in a unit of 1,000 IU. The service is a parenteral chemotherapy/immunotherapy medication administration involving a physician-, clinic-, or hospital-based drug supply for treatment of oncology indications that require asparaginase.

Service type: Injectable antineoplastic agent (asparaginase, erwinaze)

Typical site of service: Hospital outpatient department, physician office, or infusion center

Data not available in the input for additional fields.

Clinical Context

A pediatric or adult patient with acute lymphoblastic leukemia (ALL) or other malignancy requiring asparaginase therapy presents to an outpatient oncology infusion center for administration of J9019 (asparaginase [erwinaze], 1,000 IU). The patient is evaluated by the oncology nurse and supervising oncologist with review of recent labs including complete blood count, comprehensive metabolic panel, and coagulation studies to confirm eligibility for dosing. Pre-medication (e.g., antihistamine, corticosteroid) is documented when indicated to reduce hypersensitivity risk. The medication is reconstituted per institutional pharmacy protocols and administered via intramuscular or intravascular route depending on formulation and prescribing instructions. Vital signs and infusion tolerance are monitored during and after administration; adverse reactions (hypersensitivity, pancreatitis, coagulopathy) trigger escalation to the clinician and may require treatment, observation, or transfer. Documentation includes drug name, dose in IU, lot number, route, site, date/time, and relevant modifier(s) for billing. Typical sites of service are hospital outpatient infusion centers, freestanding oncology infusion clinics, or skilled nursing facilities for select patients.

Coding Specifications

Modifier	Description	When to Use
`11`	Emergency/unscheduled service	Use when the administration occurs during an emergency visit requiring immediate care beyond routine scheduling.

Taxonomy Code	Specialty	Notes
`207Q00000X`	Hematology-Oncology	Medical oncologists and pediatric hematology-oncology physicians supervise and prescribe asparaginase therapy.
`208000000X`	Pediatrics	Pediatricians (often subspecialty pediatric oncologists) manage pediatric dosing and monitoring.
`363A00000X`	Infusion Therapy	Infusion nurses and clinics providing administration and monitoring services.
`207L00000X`	Internal Medicine	Hospital-based internists or hospitalists involved in inpatient administration and complication management.
`353E00000X`	Pharmacy	Clinical pharmacists managing preparation, dosing verification, and lot tracking.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C91.0`	Acute lymphoblastic leukemia	Primary indication for asparaginase therapy as part of multi-agent chemotherapy regimens.
`C91.00`	Acute lymphoblastic leukemia not having achieved remission	Used when treating active disease requiring induction therapy including asparaginase.
`C91.01`	Acute lymphoblastic leukemia in remission	Used for maintenance or consolidation phases where asparaginase may be administered per protocol.
`C92.0`	Acute myeloblastic leukemia	Less common, but may appear in protocols using asparaginase in select regimens.
`D61.819`	Other secondary aplastic anemias	Relevant as a monitoring consideration; patients with bone marrow dysfunction require careful dosing and monitoring.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96413`	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug	Commonly billed for infusion-based chemotherapy administration when asparaginase is given intravenously and the infusion duration fits this time frame.
`96415`	Chemotherapy administration; each additional hour (list separately in addition to code for primary service)	Billed when infusion or monitoring extends beyond the initial hour for prolonged administration or observation.
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	Used when `J9019` is administered via intramuscular or subcutaneous injection rather than infusion.
`36415`	Collection of venous blood by venipuncture	Performed for pre- and post-dose laboratory monitoring required for safe administration (CBC, CMP, coagulation studies).
`99024`	Postoperative follow-up visit global — usually included in global package; used for reporting unrelated post-op care	Occasionally used to document significant follow-up care related to complications from administration when payer allows separate billing.

OpenPayer

Summary & Overview

HCPCS J9019: Asparaginase (erwinaze) Injection, 1,000 IU